LU503210B1 - A live vector vaccine of Baculovirus based on SARS-CoV-2 S protein and the application - Google Patents

A live vector vaccine of Baculovirus based on SARS-CoV-2 S protein and the application Download PDF

Info

Publication number
LU503210B1
LU503210B1 LU503210A LU503210A LU503210B1 LU 503210 B1 LU503210 B1 LU 503210B1 LU 503210 A LU503210 A LU 503210A LU 503210 A LU503210 A LU 503210A LU 503210 B1 LU503210 B1 LU 503210B1
Authority
LU
Luxembourg
Prior art keywords
sars
baculovirus
cov
protein
vac
Prior art date
Application number
LU503210A
Other languages
English (en)
Inventor
Baojing Lu
Bao Li
Original Assignee
Univ Anhui Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Anhui Medical filed Critical Univ Anhui Medical
Priority to LU503210A priority Critical patent/LU503210B1/en
Application granted granted Critical
Publication of LU503210B1 publication Critical patent/LU503210B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (2)

REVENDICATIONS LU503210
1. Le vaccin vectoriel vivant du baculovirus basé sur la protéine SARS-COV-2 S est caractérisé dans la comprenant des vecteurs de transfert recombinant PFB-S-CMV; PFB-S; Plasmides recombinants chromosomiques artificiels bactériens SARS-COV-2 CACFB-S , CACFB-S-CMV, Baculovirus recombinant VAC-S-CMV, VAC-S.
2. Le vaccin vectoriel vivant du baculovirus basé sur la protéine SAR-COV-2 S selon la revendication 1, et son application dans le domaine de l'inhibition de l'infection SARS-COV2.
LU503210A 2022-12-19 2022-12-19 A live vector vaccine of Baculovirus based on SARS-CoV-2 S protein and the application LU503210B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
LU503210A LU503210B1 (en) 2022-12-19 2022-12-19 A live vector vaccine of Baculovirus based on SARS-CoV-2 S protein and the application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LU503210A LU503210B1 (en) 2022-12-19 2022-12-19 A live vector vaccine of Baculovirus based on SARS-CoV-2 S protein and the application

Publications (1)

Publication Number Publication Date
LU503210B1 true LU503210B1 (en) 2023-06-20

Family

ID=86850790

Family Applications (1)

Application Number Title Priority Date Filing Date
LU503210A LU503210B1 (en) 2022-12-19 2022-12-19 A live vector vaccine of Baculovirus based on SARS-CoV-2 S protein and the application

Country Status (1)

Country Link
LU (1) LU503210B1 (fr)

Similar Documents

Publication Publication Date Title
CN116333161B (zh) 一种covid-19亚单位疫苗及其制备方法与应用
CN109182380B (zh) 杆状病毒表达的猪瘟e2亚单位疫苗的制备方法及应用
WO2022144040A1 (fr) Séquence nucléotidique codant pour un nouvel antigène de coronavirus, et son utilisation
CN111778264B (zh) 基于新型腺病毒载体Sad23L和/或Ad49L的新型冠状病毒肺炎疫苗
CN107190013B (zh) 一种以人Ad5复制缺陷型腺病毒为载体的寨卡病毒病疫苗
CN113293145B (zh) 一种麻疹病毒活载体新冠疫苗
KR20180002872A (ko) 신규한 배큘로바이러스 벡터 및 사용 방법
CN113913464B (zh) 一种表达载体、重组腺相关病毒及其在制备2019新型冠状病毒疫苗中的应用
WO2013098364A1 (fr) Particules de type viral (vlp) de seconde génération provenant de virus d'epstein-barr pour des fins de vaccination
Cheng et al. Incorporation of GM-CSF or CD40L enhances the immunogenicity of hantaan virus-like particles
CN110981968B (zh) 含有狂犬病病毒g蛋白的融合蛋白及其制备方法、应用和疫苗
CN113862284B (zh) 一种编码重组禽流感病毒ha蛋白的基因、病毒样颗粒、疫苗及制备与应用
CN114276969A (zh) 一种SARS-CoV-2细菌样颗粒及其在疫苗中的应用
AU2020103776A4 (en) Koi herpesvirus (khv) orf-149-based carbon nanotube supported nucleic acid vaccine and application thereof
WO2021042947A1 (fr) Conception et utilisation de vaccin à adn minicercle
LU503210B1 (en) A live vector vaccine of Baculovirus based on SARS-CoV-2 S protein and the application
CN110358741B (zh) 一种表达猪塞内卡病毒vp2基因的重组杆状病毒及其制备方法与应用
Liu et al. Expression and immunogenicity of two recombinant fusion proteins comprising foot-and-mouth disease virus structural protein VP1 and DC-SIGN-binding glycoproteins
Li et al. Development and characterization of Rift Valley fever virus-like particles
CN113896773B (zh) 重组fcv抗原及猫嵌杯病毒基因工程亚单位疫苗
CN103045544B (zh) 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用
CN113248577A (zh) 一种以腺病毒为载体的冠状病毒疫苗及其制备方法
WO2007104979A1 (fr) Particules pseudovirales du virus de la fièvre de la vallée du rift
CN116036258A (zh) 一种基于SARS-CoV-2 S蛋白的杆状病毒活载体疫苗及其应用
CN110577585A (zh) 水泡型口炎病毒包膜糖蛋白变体及其构建方法和应用

Legal Events

Date Code Title Description
FG Patent granted

Effective date: 20230620